FierceBiotech |
Novavax offers hype and hope with an RSV 'breakthrough'
FierceBiotech Novavax shares ($NVAX) surged today on the news that its vaccine for respiratory syncytial virus (RSV) proved effective in a large midstage study that company officials billed as a "historic" achievement. Long an elusive goal in development circles ... |
dinsdag 11 augustus 2015
Novavax offers hype and hope with an RSV 'breakthrough' - FierceBiotech
